

Lupus Ventures Takes Stake in Glycostem

Momentum Continues to Build in Advance of Glycostem's Pivotal 2019 Trials

OSS, Netherlands — Netherlands-based Lupus Ventures has invested €3 million in Glycostem, furthering the company's expansion and ongoing technological development. Glycostem will channel this funding primarily to production optimisation and automation.

The Lupus investment brought closer to realisation a primary goal; having in place a completely closed production system. This would in turn allow Glycostem to leverage [EMA's latest update to ATMP manufacturing](#), thereby reducing the expense of production implementation.

Troels Jordansen, Glycostem's CEO, said, "Lupus is a uniquely dynamic shareholder and investor. Their directors recognised the opportunity presented by Glycostem's technology, clinical data and management team. Benefitting from the talent and professionalism of the board of directors, we will execute, achieve milestones more quickly and move forward as a company and a technology." Jordansen adds, "Lupus has already proved to be a great asset, in terms of strategic decision-making. We look forward to a long and mutually beneficial association."

Lupus Ventures Director Cees de Wolff said, "It's not every day that an opportunity like Glycostem comes along. The very encouraging clinical trial data, the recent advancements in technology, favourable EMA regulations, as well as the powerful management team they (Glycostem) put together presents quite a package." He adds, "Investing in healthcare, particularly in innovative oncology solutions at this level, is an extremely exciting prospect. We are very much looking forward to working with Glycostem management to accelerate development of this potentially revolutionary curative product."

-more-

Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com

About Glycostem

Netherlands-based Glycostem Therapeutics BV is a clinical stage biotech company focused on developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells to treat several types of cancer. NK-cells are the body's first line of defence because of the innate ability of NK-cells to rapidly and accurately identify and destroy cells under stress, such as cancer or virally-infected cells.

Glycostem's lead product, oNKord[®], is produced in a closed system in Glycostem's state-of-the-art production facility in The Netherlands, from which the product can be distributed globally. The platform technology includes ex vivo expansion of a high number of pure and highly activated NK-cells for clinical applications. oNKord[®] successfully concluded phase I clinical trial (elderly and fragile AML patients), providing solid safety data and strong indication of clinical activity, including response on MRD. Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019.

Thanks to the six patent families, longstanding technical expertise and resources, as well as 'Orphan Drug Designation', Glycostem has secured a leadership position in the global NK-cell market.

About Lupus Ventures

Netherlands-based Lupus Ventures B.V., a family business, was built on an operational premise asserting that every entrepreneurial pursuit can benefit from an experienced partner and strategic collaborator. If Lupus invests in a developing enterprise, Lupus remains committed to that venture for the long term.

Lupus focuses on active partnerships; alliances within which Lupus may build value not only by providing capital financing, but also by contributing corporate and operational expertise. Lupus often acts quickly, investing and engaging with partners to more rapidly expand new ventures, but the company does not invest for short term gain.

-more-

Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com

Lupus Ventures and its expanding network of companies are largely concentrated in the oncology and biotech sector. Corporate energy is particularly devoted to sustainable principles and bio-based products. Lupus strives to build value, equity and capital for its partner companies, while also benefiting society in The Netherlands and beyond.

-end-

Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com